RxDoctor Payments Data

Laurence James, MD

Internal Medicine · Sweetwater, TNNPI 1932587342

Payments from drug & device makers

$9,940in general payments, 2019–2025

Across 689 payments — averaging $14.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$813
  • Amgen$637
  • Pfizer$629
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,923100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,940 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$182,329
Medicare patients
567
Services billed
2,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban364$286,462
MounjaroTirzepatide155$176,350
OzempicSemaglutide131$137,816
XeljanzTofacitinib Citrate13$87,203
JardianceEmpagliflozin94$79,366
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$78,755
TrulicityDulaglutide69$69,593
VraylarCariprazine Hcl29$49,316
Dupixent SyringeDupilumab12$46,466
JanuviaSitagliptin Phosphate41$42,300
XareltoRivaroxaban38$39,380
FarxigaDapagliflozin Propanediol40$34,887
LinzessLinaclotide50$33,568
MyrbetriqMirabegron44$27,186
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$21,942

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz$629$373,665377 claims
Lilly USA, LLCMounjaro, Trulicity$813$245,942224 claims
Novo NordiskOzempic$1,244$137,816131 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta$497$101,312135 claims
AbbVieVraylar, Linzess, Qulipta$1,076$99,18492 claims
GSKTrelegy Ellipta, Breo Ellipta$1,315$85,537105 claims
AstraZenecaFarxiga, Brilinta$363$52,06761 claims
MerckJanuvia$53$42,30041 claims
Johnson & JohnsonXarelto$150$39,38038 claims
Astellas Pharma US IncMyrbetriq$104$27,18644 claims
Sanofi-aventis U.S. LLCLantus$110$5,47722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Sweetwater

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →